6 recruiting, 3 completed, 1 active not recruiting, 1 suspended. 12 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 6, Completed 3, Active not recruiting 1, Suspended 1, Unknown 1 |
| Phase 2 | 5 | Completed 2, Recruiting 2, Active not recruiting 1 |
Follow Refractory Osteosarcoma: new trials by email Literature Review of Refractory Osteosarcoma trials Research Report on Refractory Osteosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-07-15 | 2026-07-21 |
| Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma Tegavivint, Gemcitabine - Osteosarcoma Recurrent, Osteosarcoma in Children | Phase 1 | Recruiting | Emory University | 24 | 2026-01-22 | 2026-10-19 |
| Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial FH FOLR1 ST CAR T-cells, Leukapheresis, Fludarabine - Advanced Osteosarcoma, Recurrent Osteosarcoma | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2026-01-16 | 2026-09-01 |
| IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma IM83 CAR-T Cells - Refractory Osteosarcoma, Recurrent Osteosarcoma | Phase 1 | Unknown | Beijing Immunochina Medical Science & Technology Co., Ltd. | 9 | 2024-06-15 | 2024-05-14 |
| Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate - Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Recruiting | Emory University | 24 | 2023-11-06 | 2025-12-26 |
| Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 73 | 2022-01-25 | 2026-08-05 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Cabozantinib With Topotecan-Cyclophosphamide Cabozantinib, Topotecan, Cyclophosphamide - Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma | Phase 1 | Completed | Dana-Farber Cancer Institute | 12 | 2020-12-23 | 2023-02-15 |
| Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma Docetaxel, Gemcitabine, Hydroxychloroquine - Recurrent Osteosarcoma, Refractory Osteosarcoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 31 | 2019-01-28 | 2026-05-14 |
| Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 26 | 2018-01-31 | 2024-07-15 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
Osteosarcoma (12) · Neuroblastoma (6) · Sarcoma, Ewing (3) · Hepatoblastoma (2) · Lymphoma, Non-Hodgkin (2) · Melanoma (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Rhabdomyosarcoma (2) · Wilms Tumor (2) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Desmoid Tumors (1) · Endometrial Neoplasms (1) · Hodgkin Disease (1) · Neoplasms (1)
Neoplasms by Histologic Type (12) · Neoplasms, Bone Tissue (12) · Neoplasms, Connective Tissue (12) · Neoplasms, Connective and Soft Tissue (12) · Neoplasms (11) · Sarcoma (11) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Glandular and Epithelial (6) · Neoplasms, Nerve Tissue (6) · Neoplasms, Neuroepithelial (6) · Neuroectodermal Tumors (6) · Neuroectodermal Tumors, Primitive (6) · Neuroectodermal Tumors, Primitive, Peripheral (4) · Neoplasms by Site (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)
Cyclophosphamide (3) · Biopsy (2) · Gemcitabine (2) · Specimen Handling (2) · Temozolomide (2) · X-Rays (2) · Absorptiometry, Photon (1) · Bone Density (1) · CTLA-4 Antigen (1) · Docetaxel (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Hydroxychloroquine (1) · Ipilimumab (1) · Irinotecan (1)
Children's Oncology Group (2) · Emory University (2) · National Cancer Institute (NCI) (2) · Baylor College of Medicine (1) · Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · Dana-Farber Cancer Institute (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · St. Jude Children's Research Hospital (1)
United States (11) · Canada (2) · China (1)
Crystal L Mackall (1) · Emily G Greengard (1) · John A Livingston (1) · Kelly Goldsmith, MD (1) · Leander D Timothy, MD (1) · Michelle Choe, MD (1) · Rosandra N Kaplan (1) · Sara Federico, MD (1) · Sarah B Whittle (1) · Shoba A Navai, MD (1) · Stephanie L Fetzko, MD (1) · Steven C DuBois, MD (1) · Thomas Cash, MD, MSc (1) · Yu Zhang, PhD (1)
PMID 31401903, PMID 32192573, PMID 38520670
UM1CA097452 (2), UM1CA228823 (2), U24CA224309 (1), UM1CA154967 (1)